The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Futibatinib, zimberelimab, and chemotherapy in first-line biliary tract cancer
Lorenza Rimassa, MD, Hunimed University, Milan, Italy, discusses a Phase I study (NCT04999761) of futibatinib, an FGFR1-4 inhibitor, with zimberelimab, an anti-PD-1 antibody, and chemotherapy as first-line treatment for unresectable advanced or metastatic biliary tract cancer, regardless of FGFR status. The combination showed a manageable safety profile with expected hematologic toxicities and encouraging antitumor activity, including a high response and disease control rate. These results support a planned Phase III trial comparing this regimen with investigator-choice checkpoint inhibitor plus chemotherapy. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
